Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Cupissol

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 21, 2018
[What is the best management for a spermatic cord sarcoma in 2018?]S Carrère, R Tetreau, C Honoré, et al.
British Journal of Cancer|July 29, 2010
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosisA Dufresne, F Bertucci, N Penel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2010
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neckR Mesía, F Rivera, A Kawecki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2010
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-upN Penel, A Le Cesne, B N Bui, et al.
Acta Gastro-Enterologica Belgica|March 22, 2018
Patients with primary localized high-grade sarcomas of the digestive tract excluding GIST : a retrospective study from the French sarcoma groupA de Nonneville, C Toullec, J Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trialB Bui-Nguyen, I Ray-Coquard, C Chevreau, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 22, 2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]F Mornex, L Thomas, P Mohr, et al.
British Journal of Cancer|August 11, 2011
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neckJ M Del Campo, R Hitt, P Sebastian, et al.
Melanoma Research|February 6, 2003
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanomaF Mornex, L Thomas, P Mohr, et al.
Annales De Dermatologie Et De Venereologie|February 11, 2014
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute]M-T Leccia, F Planchamp, B Sassolas, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 21, 2018
[What is the best management for a spermatic cord sarcoma in 2018?]S Carrère, R Tetreau, C Honoré, et al.
British Journal of Cancer|July 29, 2010
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosisA Dufresne, F Bertucci, N Penel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2010
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neckR Mesía, F Rivera, A Kawecki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2010
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-upN Penel, A Le Cesne, B N Bui, et al.
Acta Gastro-Enterologica Belgica|March 22, 2018
Patients with primary localized high-grade sarcomas of the digestive tract excluding GIST : a retrospective study from the French sarcoma groupA de Nonneville, C Toullec, J Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trialB Bui-Nguyen, I Ray-Coquard, C Chevreau, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 22, 2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]F Mornex, L Thomas, P Mohr, et al.
British Journal of Cancer|August 11, 2011
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neckJ M Del Campo, R Hitt, P Sebastian, et al.
Melanoma Research|February 6, 2003
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanomaF Mornex, L Thomas, P Mohr, et al.
Annales De Dermatologie Et De Venereologie|February 11, 2014
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute]M-T Leccia, F Planchamp, B Sassolas, et al.
Pageof 8